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8Drug concentrations in post-mortem femoral
blood compared with therapeutic
concentrations in plasma
Terhi Launiainen* and Ilkka OjanperäTherapeutic drug concentrations measured in plasma are of limited value as reference intervals for interpretation in
post-mortem (PM) toxicology. In this study, drug concentration distributions were studied in PM femoral venous blood from
57 903 Finnish autopsy cases representing all causes of death during an 11-year period. Cause-of-death information was
obtained from death certiﬁcates issued by forensic pathologists. Median, mean, and upper percentile (90th, 95th, 97.5th) con-
centrations were calculated for 129 drugs. To illustrate how PM median concentrations relate to established therapeutic
ranges in plasma, a PM blood/plasma relationship was calculated for each drug. Males represented 75% of the subjects and
showed a lower median age (55 yrs) than females (59 yrs). In 43% of these cases, blood alcohol concentration was higher than
0.2‰, and the median was 1.8‰. Sixty-one (47%) of the 129 drugs showed a PM blood/plasma relationship of 1. For 22 drugs
(17%), the relationship was <1, and for 46 drugs (35%), the relationship was >1. No marked correlation was found between
the PMblood/plasma relationship and the volume of distribution (Vd). For 36 drugs, more than 10%of caseswere fatal poisonings
attributed to this drug as the main ﬁnding. These drug concentration distributions based on a large database provide a helpful
reference not only to forensic toxicologists and pathologists but also to clinical pharmacologists in charge of interpreting drug
concentrations in PM cases. © 2013 The Authors. Drug Testing and Analysis published by John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher's website.
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Post-mortem (PM) toxicology aims to detect xenobiotics in autopsy
specimens, determine the concentrations of the relevant compounds,
and contribute to the interpretation of the ﬁndings for cause of death
investigations. In today's society, medicines and drugs of abuse
account for a majority of the compounds causing fatal poisonings.
Drug concentrations measured in PM blood play a key role in deter-
mining the cause and manner of death in suspected overdose cases.
In a clinical context, therapeutic and toxic drug concentrations in
plasma have been thoroughly investigated, and they are readily
available from extensive compilations.[1] These data serve as appro-
priate references in therapeutic drugmonitoring, clinical toxicology,
and monitoring of compliance.[2] Unfortunately reference plasma
concentrations are applied rather carelessly even to PM blood, as
many compilations do not clearly state whether the particular data
are from blood or plasma. Yet, an early compilation by Osselton
distinguished between plasma and PM blood values, and indicated
drug distribution in blood as a percentage in plasma for a number
of compounds.[3] In the most recent editions of the handbook by
Baselt, the blood/plasma ratio is included where available,[4]
indicating more than two-fold differences between blood and
plasma concentrations with certain drugs.
Little was known about PM drug redistribution (PMR) until the
papers by Pounder and Jones[5] and Prouty and Anderson[6]
appeared in 1990. It was realized that PM drug concentrations
are not necessarily the same as those at the time of death, as
drug levels may vary according to the sampling site and the
interval between death and specimen collection (PM interval).Drug Test. Analysis 2014, 6, 308–316 © 2013This ﬁnding gave rise to extensive research, including the investi-
gation of cardiac blood to peripheral blood concentration ratios
and the use of experimental animals.[7–11] The underlying mech-
anisms include passive drug release from drug reservoirs such as
the gastrointestinal tract, liver, lungs, and myocardium immedi-
ately after death and, later, cell autolysis and the putrefactive
process.[12] Today, it is a general conclusion that PM blood from
a femoral vein, exhibiting less PMR than central blood, should
be used for quantitative determinations on a routine basis.[13,14]
Numerous case notes and small case series have reported drug
concentrations related to fatal poisonings.[4] Although useful,
these data are very heterogeneous in terms of the origin of blood
and the quality of methods, resulting in very broad concentration
ranges with little statistical value. There is a risk that published
cases represent the higher end of fatal concentrations, because
a high concentration found for a novel drug may trigger the
publication of a case note. Ferner stated that concentrationsThe Authors. Drug Testing and Analysis published by John Wiley & Sons, Ltd.
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concentrations present before death and the deﬁnition of ‘lethal
concentrations’ is extremely difﬁcult.[15] Furthermore, Ferner
pointed out that PM concentrations have been over-interpreted
in the past, and good evidence should be required before ‘lethal
concentrations’ are deﬁned in the future.[15] Interestingly, far
fewer studies have dealt with ‘normal’ PM concentrations,
although these data would be even more important for the
interpretation of the concentrations measured in casework.
In some countries, a high autopsy rate and a high PM toxicology
ratemake it possible to generate PMdrug concentration data that is
less biased by fatal poisonings. Especially valuable data can be
obtained from laboratories that analyze a broad range of drugs
using quality-controlled methods on a routine basis. A straightfor-
ward approach to establishing normal concentrations was taken
by Jones and Holmgren, utilizing Swedish material under
well-deﬁned conditions.[16] Using a database gathered from 24
876 PM femoral blood samples, they presented concentration distri-
butions of the 25 drugs most frequently identiﬁed representing all
causes of death, using 50th, 90th, 95th, and 97.5th percentiles.
The advantage of this approach is that representative data can be
extracted relatively simply from a comprehensive laboratory
database without including cause-of-death information.
Our objectives were to exploit an even larger database in order
to establish concentration distributions in PM blood for 129
drugs representing all causes of death and to evaluate the gen-
eral applicability of the concentration data by comparison with
the Jones and Holmgren study.[16] We present the proportion of
fatal poisonings attributed to each drug to facilitate interpreta-
tion. In addition, we compare the PM concentrations found in
blood with the average therapeutic ranges in plasma, as exempli-
ﬁed recently by Linnet,[17] in order to get a general idea of the
prevalence and magnitude of the differences.Materials and methods
Forensic toxicology in Finland
In Finland, a sudden or unexpected death leads to an inquest
conducted by the police. If considered necessary, the police launch
a medico-legal investigation by a forensic pathologist. An investiga-
tion is always conducted when a death is not known to be caused
by a disease, or is known to be related to an accident, crime, suicide,
poisoning, occupational illness, medical procedure, or war. This also
includes deaths that do not occur under medical care or are other-
wise sudden or unclear. Even reasonable doubt about the causes
mentioned above is enough for an investigation and no permission
from the next-of-kin is needed. Approximately 50 000 Finns die
each year and a medico-legal autopsy is performed in about 11
000 cases. Toxicological samples are collected after the decisionTable 1. Characteristics of autopsy cases with comprehensive post-morte
Autopsies Age, years
Gender N Mean ± SD (median) highest
Male 43,458 53.4 ± 16.5 (55) 102
Female 14,428 58.3 ± 18.5 (59) 99
All 57,903b 54.6 ± 17.1 (56) 102
aLimit of quantiﬁcation for blood ethanol in post-mortem blood.
bNo age data was available for 15 cadavers that remained unidentiﬁed.
Drug Test. Analysis 2014, 6, 308–316 © 2013 The Authors. Drug
published by John Wby the forensic pathologist. All toxicological analyses are performed
in one laboratory at the Department of Forensic Medicine of Hjelt
Institute, University of Helsinki. This leads to toxicological analysis
of over 6500 cases a year, which represents over 13% of all deaths
nationwide. The laboratory has been accredited since 1997 by the
Finnish Centre for Metrology and Accreditation (FINAS).
The samples undergo screening and quantiﬁcation analysis for
legal and illicit drugs and poisonous substances, and the analysis
results are then sent to the forensic pathologist and stored in the
laboratory's toxicology database. Later, a death certiﬁcate, including
the cause andmanner of death, is issued by the forensic pathologist
and the appropriate data are integrated in the toxicology database.
Toxicological analysis
The PM interval from death to autopsy was on average ﬁve days,
and on arrival at morgue the cadavers were put in cold storage
(+3–5 °C) pending autopsy. The concentration data were ac-
quired from femoral venous blood taken at autopsy. The samples,
containing 1% NaF to prevent microbial processes, were stored at
+4 °C until and during the laboratory investigation, which in most
cases was completed within 12 days of arrival of the sample.
A multi-technique approach was used for the comprehensive
toxicological analysis of blood and urine samples. Urine samples
were analysed using the laboratory's routine qualitative drug
screening methods involving immunoassay for drugs of abuse
and liquid chromatography/time-of-ﬂight mass spectrometry (LC-
TOF-MS) for a broad range of therapeutic and abused illicit
drugs.[18,19] Simultaneously, blood samples were quantitatively
monitored for about 200 drugs using the following three methods:
For acidic and neutral drugs, dual-column gas chromatography
with nitrogen phosphorus detection (GC-NPD)[20] was used until
replaced in February 2007 by a method based on GC coupled with
mass spectrometry (GC-MS).[21] For benzodiazepines, a GC method
with electron capture detection (GC-ECD)[22] was used until March
2010, after which a method based on GC and negative-ion chemi-
cal ionization MS (GC-NCIMS)[23] was adopted for routine use. A
dual-column GC-NPD method was used for basic drug screen-
ing.[24] Conﬁrmation and additional determinations were carried
out by GC-MS and LC coupled to triple quadrupole MS/MS for
drugs not covered by the quantitative monitoring methods. The
analytical procedure covered the majority of psychotropic drugs
available on the legal and illicit markets in Finland, with special
emphasis on abused substances. The validation data are summa-
rized in an online supplementary ﬁle.
Data reﬁning
During the 11-year study period (1 January 2000 – 31 December
2010), drug ﬁndings in PM femoral venous blood from 57 903m drug analysis completed
Blood alcohol ≥ 0.2‰a Blood alcohol concentration ‰
N Mean ± SD (median) highest
20,193 1.85 ± 1.11 (1.80) 7.60
4685 1.79 ± 1.12 (1.70) 8.50
24,879 1.84 ± 1.16 (1.80) 8.50
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0autopsy cases were entered in the toxicology database (Table 1).
From this material, the drugs that had been detected at least 50
times in PM blood were selected. These data also included ﬁnd-
ings below the limit of quantiﬁcation (LOQ) reported as ‘positive’.
Due to changes in the quantitative analytical methods, there
had been some signiﬁcant changes in the LOQ for some drugs
in the course of time. For uniformity, the benzodiazepine and
nifedipine results included were obtained solely from the 53
095 cases analysed by GC-ECD.[22] Similarly, the results included
for the acidic/neutral drugs phenobarbital, phenytoin, ibuprofen,
indometacin, ketoprofen, levetiracetam, meprobamate,
naproxen, oxcarbazepine, theophylline, and warfarin were
obtained solely from the 23 385 cases analysed by GC-MS.[21] If
there had been only a slight change in LOQ, all results were
included and both LOQ values indicated.
Median, mean and upper percentile (90th, 95th, 97.5th) concen-
trations (mg/L) were calculated from ﬁndings with a numerical
value for the drug concentration (Table 2). The proportion of fatal
drug poisonings caused by each of the drugs, as themost important
ﬁnding, was obtained from death certiﬁcate data. The forensic
pathologist had provided the cause of death according to the 10th
revision of the International Classiﬁcation of Diseases (ICD-10, WHO)
and the ATC code (Anatomical Therapeutic Chemical classiﬁcation,
WHO) of the particular drug as an external cause of death.
For each drug, the relationship of the median PM drug
concentration in blood to the therapeutic range in plasma (PM
blood/plasma relationship) was calculated as follows: drugs with
a median PM concentration within the established therapeutic
range in plasma[1] were given a relationship of 1; for drugs with
a median PM concentration below the therapeutic range, the
median concentration was divided by the lower limit of the
therapeutic range, resulting in a relationship lower than 1; for
drugs with a median PM concentration above the therapeutic
range, the median concentration was divided by the upper limit
of the therapeutic range, resulting in a relationship higher than
1. The midpoint of the volume of distribution range (Vd, L/kg)
was determined for each drug based on literature data.[4,25]Results
Overview
Table 1 shows characteristics of the 57 903 autopsy cases from
the study period between 1 January 2000 and 31 December
2010, for which a comprehensive PM drug analysis was
completed. Males represented 75% of the subjects and showed
a lower median age than females (p<0.001 Mann-Whitney Test).
In 43% of these cases, blood alcohol concentration (BAC) was
over the limit of quantiﬁcation (0.2‰ or 0.2 g/kg), and the
median BAC was 1.8‰.
Drug concentrations in PM femoral venous blood
Table 2 shows the PM concentration distributions of the 129
drugs most frequently found in autopsy cases in alphabetical
order. Table 2 also gives for each drug the LOQ, proportion of
fatal poisonings as the main ﬁnding, the established therapeutic
concentration range in plasma[1] and the relationship of PM
median concentration to therapeutic range (PM blood/plasma
relationship). For most drugs, the arithmetic means of PM
concentrations were much higher than the median values,
indicating skewed distributions.wileyonlinelibrary.com/journal/dta © 2013 The Authors. D
published by JohSixty-one (47%) of the 129 drugs showed a PM blood/plasma
relationship of one. For 22 drugs (17%), the relationship was
below 1, and for 46 drugs (35%), the relationship was higher than
1. Figure 1 indicates the 36 drugs for which more than 10% of
cases were fatal poisonings attributed to this drug as the main
ﬁnding.
All PM blood/plasma relationships were plotted against the
midpoint of the Vd range. No marked correlation was found,
and even the drugs with a PM blood/plasma relationship of one
showed a wide variation along the y-axis (Vd midpoint).Discussion
Our study provides reference data to aid interpretation of drug
concentrations in PM blood by listing the normal (median) and
elevated PM femoral venous blood concentrations of 129 drugs,
derived from the extensive Finnish toxicology database. The
approach of our study is in accordance with the paper by Jones
and Holmgren in 2009 for 25 drugs based on the Swedish data-
base.[16] However, the data published here is more comprehen-
sive and the ranking list of the most frequently detected drugs
is different, although the age, gender and alcohol statistics are
similar. The median concentrations for the majority of drugs
included in both studies are very close to each other despite
small differences in the LOQs applied (Figure 2). There are some
exceptions though: the dextropropoxyphene median concentra-
tion in our study is 2.6 mg/L vs. 0.8 mg/L in the Swedish material,
codeine 0.16 mg/L vs. 0.05 mg/L, and amphetamine 0.28 mg/L vs.
0.5 mg/L, respectively.[16] These differences can be partly
explained by the different LOQs and partly by the different abuse
practices between the two countries. Information on the propor-
tion of fatal poisonings attributed to each drug was not included
in the Swedish study.
A signiﬁcant contribution to illustrating the differences
between normal and fatal concentrations under well-deﬁned
conditions was made by the Swedish scientists Druid and
Holmgren.[26] They were able to report concentrations of 83
drugs in PM femoral blood from one-substance poisonings,
multi-substance poisonings, and from other causes of death
without incapacitation due to drugs. The concentrations were
compared with blood concentrations detected in drivers
suspected of being under the inﬂuence of drugs. In the further
study by Reis et al.,[27] the same strategy was used for 15
anti-depressant drugs but therapeutic drug monitoring material
was used for comparison. These elaborate studies provide very
useful data but, inevitably, strict inclusion criteria greatly
reduce the amount of original data, and for many drugs one-
substance poisonings do not exist at all. With the exception
of dextropropoxyphene (2.6 mg/L in our study vs. 0.2 mg/
L[26]) and moclobemide (1.9 mg/L vs. 0.6 mg/L[26,27]) the
median concentrations of the present study were in accor-
dance with the results of these two studies when compared
with the median concentrations of groups ‘other cause of
death without incapacitation due to drugs’[26] and ‘certiﬁed
other cause of death in which the circumstances exclude the
possibility of incapacitation by drugs’.[27]
A PM blood/plasma relationship was introduced to illustrate
how the median PM blood drug concentrations relate to the
established therapeutic ranges in plasma. In our study, most neu-
tral and acidic drugs, such as benzodiazepines, anti-epileptics,
non-steroidal anti-inﬂammatory drugs, and paracetamol, had arug Testing and Analysis
n Wiley & Sons, Ltd.
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y Johmedian concentration within or below the therapeutic range,
exhibiting a PM blood/plasma relationship ≤1. In particular, drugs
that are extensively plasma bound, such as benzodiazepines and
warfarin,[21,28] had lower PM blood concentrations. For some
drugs the low relationship could be explained by their pattern
of use, for example, lidocaine in resuscitation. A majority of ﬁnd-
ings below the LOQ for a certain drug indicates a need to de-
velop a method with better sensitivity. As for basic drugs, a PM
blood/plasma relationship >1 was commonly found, and this is
thought to be largely due to PMR. Anti-depressants possessed a
relatively high relationship, ﬂuoxetine having a value of one but
the other anti-depressants ranging from 1.2 for sertraline to 4.7
for paroxetine. Anti-psychotics showed more variation:
chlorprothixene, haloperidol, perphenazine, risperidone, thiorida-
zine and zuclopenthixol had a value of one but the other anti-
psychotics ranged from 1.8 for clozapine to 24 for promazine.
In a recent review, Linnet[17] compared the PM normal concen-
tration intervals of drugs with their therapeutic serum levels. Uti-
lizing predominantly PM concentrations from the Swedish
studies[26,27] and therapeutic concentrations from the list issued
by The International Association of Forensic Toxicologists (TIAFT),
Linnet found that the ratio between the upper limits ranged from
0.13 to 11.3 for 57 compounds with a median value of 1.5. Linnet
also concluded that highly water-soluble drugs with a low pro-
pensity for redistribution, such as meprobamate, carbamazepine,
and theophylline, had a tendency towards a low ratio, which is
also evident in our study. For anti-depressants, on the other
hand, the ratio was relatively high, ranging from 0.6 to 4.7 with
a median of 2.4. For anti-psychotics, the ratio ranged from 0.2
to 11.3 with a median of 1.4. These ﬁndings are fairly consistent
with our present results, although the calculation basis is slightly
different.
A high Vd may refer to extensive PMR and a high PM blood/
plasma relationship. Hydroxychloroquine has a notoriously high
Vd (580–815 L/kg
[4]), and in our study it possessed the highest
PM blood/plasma relationship of all (100). However, no straight-
forward correlation between Vd and PM blood/plasma relation-
ship could be found in our study.
Due to the high prevalence of medico-legal autopsies in
Finland, a great proportion of PM toxicological investigations
concern non-poisoning cases. Fatal drug poisonings comprise ap-
proximately 8% and all fatal poisonings approximately 15% of all
toxicologically investigated cases. Consequently, the median
drug concentrations reported in Table 2 are generally likely to
reﬂect normal PM concentrations. However, there were 36 drugs
with more than 10% of cases being fatal poisonings attributed to
this particular drug (Figure 1), and for these drugs the normal
concentration is probably lower than the median. The inﬂuence
of the prevalence of multi-drug and alcohol use cannot be
excluded, but in a previous study, signiﬁcant pharmacokinetic
interactions were shown to be rare.[29] When assessing the main
ﬁndings, the forensic pathologists did not have access to the
concentration distributions published here, so the results are
not biased in that sense.
The drugs frequently associated with fatal poisonings are
predominantly opioids, anti-psychotics and anti-depressants.
Other drugs include hypnotics and sedatives, some cardiovascu-
lar drugs, and amphetamine. As we have shown earlier, for strong
opioids of abuse, such as buprenorphine and methadone, their
PM concentration plays a somewhat limited role in assessing
the cause of death.[30,31] The same is partly true for amphetamine
and other drugs for which the development of tolerancerug Testing and Analysis
n Wiley & Sons, Ltd.
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Figure 1. Thirty-six drugs with more than 10% of fatal poisonings attributed to this drug as the main ﬁnding
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1
5becomes important. However, these drugs were included in this
study to give an insight into their concentration distribution in
PM blood.
Proper interpretation of PM concentrations is crucial in many
types of expert opinions. As exempliﬁed with the calcium chan-
nel blocker amlodipine, a PM concentration of 0.07 mg/L found
in a car driver killed in a trafﬁc accident would easily be
misinterpreted as serious intoxication resulting in impairment if
compared to clinical plasma reference concentrations only
(normal/therapeutic 0.003-0.015 mg/L, toxic (from) 0,088 mg/
L[1]). This would in term have insurance judicial implications.
However, the present data show that this ﬁnding represents the
median (normal) PM concentration of the 313 cases analyzed,
including only few poisoning cases, and consequently there is
no reason to suspect impairment based on the PM concentration
alone.
The toxicologist often needs to also consider the role of active
metabolites – for example, for tricyclic anti-depressants and
codeine – and also the ratio of parent drug to metabolite (active
or inactive). Such data is commonly used as an additional tool to
differentiate between chronic and acute ingestion and theDrug Test. Analysis 2014, 6, 308–316 © 2013 The Authors. Drug
published by John Wlikelihood of a drug related death. Clinical plasma reference
concentrations, let alone post-mortem femoral blood concentra-
tions, are not readily available for many metabolites, but such
data would be of obvious interest to generate and collate,
notwithstanding that this would be a very laborious task. Of
course, such work would also rely on reference standards of these
metabolites, many of which are not currently obtainable.Conclusions
The present study, based on extensive consistent high-quality
toxicology data from PM femoral venous blood (59 903 cases),
extends our knowledge of how to interpret drug concentrations
within the medico-legal context. The median PM concentrations
give an idea of the ‘normal’ PM concentration range and the
upper percentile concentrations indicate possible overdose
levels. As to common drugs, the results were in good agreement
with previous studies,[16,26,27] suggesting that PM reference
concentrations are applicable on an international basis. The pro-
portion of fatal poisonings reported with each drug helps in
assessing the concentration distribution further. However, PM
toxicology results should always be interpreted in relation to
the case as an entity. Our study demonstrates that using clinical
therapeutic ranges in plasma to interpret PM toxicology results
would commonly lead to misjudgement of a normal PM concen-
tration as a lethal level.References
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